BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 38726632)

  • 1. Fluorine-18 fluorodeoxyglucose uptake change in liver, mediastinal blood pool, and lymphoid cell-rich organs during programmed cell death-1 immunotherapy in lymphoma.
    Guo L; Wang R; Shen G
    Nucl Med Commun; 2024 May; ():. PubMed ID: 38726632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intra-patient Variability of FDG Standardized Uptake Values in Mediastinal Blood Pool, Liver, and Myocardium during R-CHOP Chemotherapy in Patients with Diffuse Large B-cell Lymphoma.
    Kim SJ; Yi HK; Lim CH; Cho YS; Choi JY; Choe YS; Lee KH; Kim BT; Moon SH
    Nucl Med Mol Imaging; 2016 Dec; 50(4):300-307. PubMed ID: 27994685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive
    Schwenck J; Schörg B; Fiz F; Sonanini D; Forschner A; Eigentler T; Weide B; Martella M; Gonzalez-Menendez I; Campi C; Sambuceti G; Seith F; Quintanilla-Martinez L; Garbe C; Pfannenberg C; Röcken M; la Fougere C; Pichler BJ; Kneilling M
    Theranostics; 2020; 10(2):925-937. PubMed ID: 31903160
    [No Abstract]   [Full Text] [Related]  

  • 4. Can physiologic colonic [
    Sachpekidis C; Stein-Thoeringer CK; Kopp-Schneider A; Weru V; Dimitrakopoulou-Strauss A; Hassel JC
    Eur J Nucl Med Mol Imaging; 2023 Oct; 50(12):3709-3722. PubMed ID: 37452874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy.
    Sjöholm T; Korenyushkin A; Gammelgård G; Sarén T; Lövgren T; Loskog A; Essand M; Kullberg J; Enblad G; Ahlström H
    Cancer Imaging; 2022 Dec; 22(1):76. PubMed ID: 36575477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting programmed death-ligand 1 (PD-L1) expression with fluorine-18 fluorodeoxyglucose ([
    Hughes DJ; Josephides E; O'Shea R; Manickavasagar T; Horst C; Hunter S; Tanière P; Nonaka D; Van Hemelrijck M; Spicer J; Goh V; Bille A; Karapanagiotou E; Cook GJR
    Eur Radiol; 2024 Feb; ():. PubMed ID: 38388716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Association Between Liver and Tumor [
    Wu X; Bhattarai A; Korkola P; Pertovaara H; Eskola H; Kellokumpu-Lehtinen PL
    Mol Imaging Biol; 2017 Oct; 19(5):787-794. PubMed ID: 28144908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT.
    Nobashi T; Baratto L; Reddy SA; Srinivas S; Toriihara A; Hatami N; Yohannan TK; Mittra E
    Clin Nucl Med; 2019 Apr; 44(4):e272-e279. PubMed ID: 30688730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Fever on
    Yao Y; Cheng J; Su M; Ou X
    Mol Imaging Biol; 2020 Aug; 22(4):1116-1123. PubMed ID: 32100227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Standardized uptake value based evaluation of lymphoma by FDG and FLT PET/CT.
    Wang R; Zhu H; Chen Y; Li C; Li F; Shen Z; Tian J; Yu L; Xu B
    Hematol Oncol; 2014 Sep; 32(3):126-32. PubMed ID: 23996464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there a link between very early changes of primary and secondary lymphoid organs in
    Seith F; Forschner A; Weide B; Gückel B; Schwartz M; Schwenck J; Othman AE; Fenchel M; Garbe C; Nikolaou K; Schwenzer N; la Fougère C; Pfannenberg C
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32753543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of standardized uptake values in normal structures between PET/CT and PET/MRI in an oncology patient population.
    Kershah S; Partovi S; Traughber BJ; Muzic RF; Schluchter MD; O'Donnell JK; Faulhaber P
    Mol Imaging Biol; 2013 Dec; 15(6):776-85. PubMed ID: 23632951
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Derlin T; Schultze-Florey C; Werner RA; Möhn N; Skripuletz T; David S; Beutel G; Eder M; Ross TL; Bengel FM; Ganser A; Koenecke C
    Ann Nucl Med; 2021 Jan; 35(1):132-138. PubMed ID: 33174144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor metabolic and secondary lymphoid organ metabolic markers on 18F-fludeoxyglucose positron emission tomography predict prognosis of immune checkpoint inhibitors in advanced lung cancer.
    Jin P; Bai M; Liu J; Yu J; Meng X
    Front Immunol; 2022; 13():1004351. PubMed ID: 36341372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Standard uptake value and metabolic tumor volume of ¹⁸F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer.
    Huang W; Zhou T; Ma L; Sun H; Gong H; Wang J; Yu J; Li B
    Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1628-35. PubMed ID: 21617977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Tumor Burden on Reference Tissue Standardized Uptake for PET Imaging: Modification of PERCIST Criteria.
    Viglianti BL; Wale DJ; Wong KK; Johnson TD; Ky C; Frey KA; Gross MD
    Radiology; 2018 Jun; 287(3):993-1002. PubMed ID: 29558296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Change of maximum standardized uptake value slope in dynamic triphasic [18F]-fluorodeoxyglucose positron emission tomography/computed tomography distinguishes malignancy from postradiation inflammation in head-and-neck squamous cell carcinoma: a prospective trial.
    Anderson CM; Chang T; Graham MM; Marquardt MD; Button A; Smith BJ; Menda Y; Sun W; Pagedar NA; Buatti JM
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):472-9. PubMed ID: 25680593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased 18F-FDG uptake within the reticuloendothelial system in patients with active lung cancer on PET imaging may indicate activation of the systemic immune response.
    Bural GG; Torigian DA; Chen W; Houseni M; Basu S; Alavi A
    Hell J Nucl Med; 2010; 13(1):23-5. PubMed ID: 20411166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics.
    Seban RD; Nemer JS; Marabelle A; Yeh R; Deutsch E; Ammari S; Moya-Plana A; Mokrane FZ; Gartrell RD; Finkel G; Barker L; Bigorgne AE; Schwartz LH; Saenger Y; Robert C; Dercle L
    Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2298-2310. PubMed ID: 31346755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.